Potential diagnostic markers for disseminated intravascular coagulation of sepsis

Blood Reviews

Volumn 30, Issue 2, 2016, Pages 149-155

  Iba, Toshiaki ^a   Ito, Takashi ^b   Maruyama, Ikuro ^b   Jilma, Bernd ^c   Brenner, Thorsten ^d   Müller, Marcella C A ^e   Juffermans, Nicole P ^e   Thachil, Jecko ^f  

^a JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antithrombin; Coagulation; Disseminated intravascular coagulation; High mobility group box protein; Histones; Protein C; Thrombomodulin; Von willebrand factor

Indexed keywords

ANTITHROMBIN; FIBRINOGEN; HIGH MOBILITY GROUP B1 PROTEIN; LEUKOCYTE ELASTASE; PROTEIN C; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ANTICOAGULANT AGENT; BIOLOGICAL MARKER;

DISEASE ASSOCIATION; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART FAILURE; HEMOSTASIS; HUMAN; NONHUMAN; NUCLEOSOME; PATHOPHYSIOLOGY; PATIENT MONITORING; POINT OF CARE TESTING; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; SEPSIS; SEPTIC SHOCK; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; VISCOELASTICITY; BLOOD; BLOOD CLOTTING TEST; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; METABOLISM; PROCEDURES; STANDARDS;

ADAMTS13 PROTEIN; ANTICOAGULANTS; BIOMARKERS; BLOOD COAGULATION TESTS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; SEPSIS; VON WILLEBRAND FACTOR;

EID: 84960939903     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2015.10.002     Document Type: Review

References (79)

1. Taylor F.B., Toh C.H., Hoots W.K., Wada H., Levi M. Scientific Subcommittee on DisseminatedIntravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
2. Wada H., Thachil J., Di Nisio M., Mathew P., Kurosawa S., Gando S., et al. The scientific standardization committee on DIC of the international society on thrombosis haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013 Feb, 4. 10.1111/jth.12155.
3. Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British committee for standards in haematology. Br J Haematol 2009, 145:24-33.
4. Fourrier F., Chopin C., Goudemand J., Hendrycx S., Caron C., Rime A., et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992, 101:816-823.
5. Macias W.L., Nelson D.R. Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 2004, 32:S223-S228.
6. Rodeghiero F., Mannucci P.M., Vigano S., Barbui T., Gugliotta L., Cortellaro M., et al. Liver dysfunction rather than intravascular coagulation as the main cause of low protein C and antithrombin III in acute leukemia. Blood 1984, 63:965-969.
7. Sié P., Letrenne E., Caranobe C., Genestal M., Cathala B., Boneu B. Factor II related antigen and antithrombin III levels as indicators of liver failure in consumption coagulopathy. Thromb Haemost 1982, 47:218-220.
8. Jordan R.E., Kilpatrick J., Nelson R.M. Heparin promotes the inactivation of antithrombin by neutrophil elastase. Science 1987, 237:777-779.
9. Seitz R., Wolf M., Egbring R., Havemann K. The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution. Eur J Haematol 1989, 43:22-28.
10. Cauchie P., Cauchie C., Boudjeltia K.Z., Carlier E., Deschepper N., Govaerts D., et al. Diagnosis and prognosis of overt disseminated intravascular coagulation in a general hospital - meaning of the ISTH score system, fibrin monomers, and lipoprotein-C-reactive protein complex formation. Am J Hematol 2006, 81:414-419.
11. Iba T., Yagi Y., Kidokoro A. The role of the endothelium in changes in procoagulant activity in sepsis. J Am Coll Surg 1998, 187:321-329.
12. Pettila V., Pentti J., Pettila M., Takkunen O., Jousela I. Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med 2002, 30:271-275.
13. Iba T., Kidokoro A., Fukunaga M., Sugiyama K., Kato H. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 2005, 23:25-29.
14. Iba T., Gando S., Murata A., Kushimoto S., Saitoh D., Eguchi Y., et al. Predicting the severity of SIRS-associated coagulopathy with hemostatic molecular markers and vascular endothelial injury markers. J Trauma 2007, 63:1093-1098.
15. Choi Q., Hong K.H., Kim J.E., Kim H.K. Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients with underlying sepsis or severe infection. Ann Lab Med 2014, 34:85-91.
16. Koyama K., Madoiwa S., Nunomiya S., Koinuma T., Wada M., Sakata A., et al. Combination of thrombin-antithrombin complex, plasminogen activator inhibitor-1, and protein C activity for early identification of severe coagulopathy in initial phase of sepsis: a prospective observational study. Crit Care 2014, 18:R13.
17. Yanagida Y., Gando S., Sawamura A., Hayakawa M., Uegaki S., Kubota N., et al. Normal prothrombinase activity, increased systemic thrombin activity, and lower antithrombin levels in patients with disseminated intravascular coagulation at an early phase of trauma: comparison with acute coagulopathy of trauma-shock. Surgery 2013, 154:48-57.
18. Guitton C., Gerard N., Sebille V., Bretonniere C., Zambon O., Villers D., et al. Early rise in circulating endothelial protein C receptor correlates with poor outcome in severe sepsis. Intensive Care Med 2011, 37:950-956.
19. Iba T., Saitoh D. Efficacy of antithrombin in preclinical and clinical application for sepsis-associated disseminated intravascular coagulation. J Intensive Care 2014, 2:66.
20. Iba T., Saito D., Wada H., Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a prospective multicenter survey. Thromb Res 2012, 130:e129-e133.
21. Iba T., Saitoh D., Wada H., Asakura H. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey. Crit Care 2014, 18:497.
22. Ammollo C.T., Semeraro F., Xu J., Esmon N.L., Esmon C.T. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost 2011, 9:1795-1803.
23. Conway E.M. Thrombomodulin and its role in inflammation. Semin Immunopathol 2012, 34:107-125.
24. Isermann B., Hendrickson S.B., Zogg M., Wing M., Cummiskey M., Kisanuki Y.Y., et al. Endothelium-specific loss of murine thrombomodulin disrupts the protein C anticoagulant pathway and causes juvenile-onset thrombosis. J Clin Invest 2001, 108:537-546.
25. Furuno T., Mitsuyama T., Hidaka K., Tanaka T., Hara N. The role of neutrophil elastase in human pulmonary artery endothelial cell injury. Int Arch Allergy Immunol 1997, 112:262-269.
26. Wada H., Ohiwa M., Kaneko T., Tamaki S., Tanigawa M., Shirakawa S., et al. Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 1992, 39:20-24.
27. Kinasewitz G.T., Yan S.B., Basson B., Comp P., Russell J.A., Cariou A., et al. Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 2004, 8:R82-R90.
28. Boehme M.W., Deng Y., Raeth U., Bierhaus A., Ziegler R., Stremmel W., et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology 1996, 87:134-140.
29. Uehara S., Gotoh K., Handa H. Separation and characterization of the molecular species of thrombomodulin in the plasma of diabetic patients. Thromb Res 2001, 104:325-332.
30. Öhlin A.-K., Larsson K., Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost 2005, 3:976-982.
31. Saito H., Maruyama I., Shimazaki S., Yamamoto Y., Aikawa N., Ohno R., et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007, 5:31-41.
32. Ito T., Maruyama I. Thrombomodulin: protectorate god of the vasculature in thrombosis and inflammation. J Thromb Haemost 2011, 9(Suppl 1):168-173.
33. Yamakawa K., Ogura H., Fujimi S., Morikawa M., Ogawa Y., Mohri T., et al. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis. Intensive Care Med 2013, 39:644-652.
34. https://clinicaltrials.gov/ct2/show/NCT01598831?term=ART-123&rank=2.
35. Sandset P.M., Warn-Cramer B.J., Rao L.V., Maki S.L., Rapaport S.I. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci U S A 1991, 88:708-712.
36. Sandset P.M., Warn-Cramer B.J., Maki S.L., Rapaport S.I. Immunodepletion of extrinsic pathway inhibitor sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalized shwartzman reaction. Blood 1991, 78:1496-1502.
37. Huang Z.F., Higuchi D., Lasky N., Broze G.J. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997, 90:944-951.
38. Dong J.F. Cleavage of ultra-large von willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost 2005, 3:1710-1716.
39. Huck V., Schneider M.F., Gorzelanny C., Schneider S.W. The various states of von willebrand factor and their function in physiology and pathophysiology. Thromb Haemost 2014, 111:598-609.
40. Kremer Hovinga J.A., Zeerleder S., Kessler P., Romani de Wit T., van Mourik J.A., Hack C.E., et al. ADAMTS-13, von willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost 2007, 5:2284-2290.
41. Reiter R.A., Varadi K., Turecek P.L., Jilma B., Knöbl P. Changes in ADAMTS13 (von-willebrand-factor-cleaving protease) activity after induced release of von willebrand factor during acute systemic inflammation. Thromb Haemost 2005, 93:554-558.
42. Brott D.A., Katein A., Thomas H., Lawton M., Montgomery R.R., Richardson R.J., et al. Evaluation of von willebrand factor and von willebrand factor propeptide in models of vascular endothelial cell activation, perturbation, and/or injury. Toxicol Pathol 2014, 42:672-683.
43. Habe K., Wada H., Ito-Habe N., Hatada T., Matsumoto T., Ohishi K., et al. Plasma ADAMTS13, von willebrand factor (VWF) and VWF propeptide profiles in patients with DIC and related diseases. Thromb Res 2012, 129:598-602.
44. Hyun J., Kim H.K., Kim J.E., Lim M.G., Jung J.S., Park S., et al. Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. Thromb Res 2009, 124:75-79.
45. Martin K., Borgel D., Lerolle N., Feys H.B., Trinquart L., Vanhoorelbeke K., et al. Decreased ADAMTS-13 (a disintegrin-like and metalloprotease with thrombospondin type 1 repeats) is associated with a poor prognosis in sepsis-induced organ failure. Crit Care Med 2007, 35:2375-2382.
46. Hyseni A., Kemperman H., de Lange D.W., Kesecioglu J., de Groot P.G., Roest M. Active von willebrand factor predicts 28-day mortality in patients with systemic inflammatory response syndrome. Blood 2014, 123:2153-2156.
47. Claus R.A., Bockmeyer C.L., Budde U., Kentouche K., Sossdorf M., Hilberg T., et al. Variations in the ratio between von willebrand factor and its cleaving protease during systemic inflammation and association with severity and prognosis of organ failure. Thromb Haemost 2009, 101:239-247.
48. Nguyen T.C., Liu A., Liu L., Ball C., Choi H., May W.S., et al. Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis. Haematologica 2007, 92:121-124.
49. Ono T., Mimuro J., Madoiwa S., Soejima K., Kashiwakura Y., Ishiwata A., et al. Severe secondary deficiency of von willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006, 107:528-534.
50. Lei X., Reheman A., Hou Y., Zhou H., Wang Y., Marshall A.H., et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014, 111:279-289.
51. Levi M., Opal S.M. Coagulation abnormalities in critically ill patients. Crit Care 2006, 10:222.
52. Amaral A., Opal S.M., Vincent J.L. Coagulation in sepsis. Intensive Care Med 2004, 30:1032-1040.
53. Levi M., Meijers J.C. DIC: which laboratory tests are most useful. Blood Rev 2011, 25:33-37.
54. Toh C.H., Samis J., Downey C., Walker J., Becker L., Brufatto N., et al. Biphasic transmittance waveform in the APTT coagulation assay is due to the formation of a Ca(++)-dependent complex of C-reactive protein with very-low-density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002, 100:2522-2529.
55. Bakhtiari K., Meijers J.C., de Jonge E., Levi M. Prospective validation of the international society of thrombosis and haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004, 32:2416-2421.
56. Muller M.C., Meijers J.C., Vroom M.B., Juffermans N.P. Utility of thromboelastography and/or thromboelastometry in adults with sepsis: a systematic review. Crit Care 2014, 18:R30.
57. Sivula M., Pettila V., Niemi T.T., Varpula M., Kuitunen A.H. Thromboelastometry in patients with severe sepsis and disseminated intravascular coagulation. Blood Coagul Fibrinolysis 2009, 20:419-426.
58. Brenner T., Schmidt K., Delang M., Mehrabi A., Bruckner T., Lichtenstern C., et al. Viscoelastic and aggregometric point-of-care testing in patients with septic shock - cross-links between inflammation and haemostasis. Acta Anaesthesiol Scand 2012, 56:1277-1290.
59. Ostrowski S.R., Windelov N.A., Ibsen M., Haase N., Perner A., Johansson P.I. Consecutive thrombelastography clot strength profiles in patients with severe sepsis and their association with 28-day mortality: a prospective study. J Crit Care 2013, 317:e1-11.
60. Soerensen K.E., Olsen H.G., Skovgaard K., Wiinberg B., Nielsen O.L., Leifsson P.S., et al. Disseminated intravascular coagulation in a novel porcine model of severe Staphylococcus aureus sepsis fulfills human clinical criteria. J Comp Pathol 2013, 149:463-474.
61. Spiel A.O., Mayr F.B., Firbas C., Quehenberger P., Jilma B. Validation of rotation thrombelastography in a model of systemic activation of fibrinolysis and coagulation in humans. J Thromb Haemost 2006, 4:411-416.
62. Sharma P., Saxena R. A novel thromboelastographic score to identify overt disseminated intravascular coagulation resulting in a hypocoagulable state. Am J Clin Pathol 2010, 134:97-102.
63. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
64. Andersson U., Tracey K.J. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 2011, 29:139-162.
65. Ito T., Kawahara K., Nakamura T., Yamada S., Nakamura T., Abeyama K., et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats. J Thromb Haemost 2007, 5:109-116.
66. Hatada T., Wada H., Nobori T., Okabayashi K., Maruyama K., Abe Y., et al. Plasma concentrations and importance of high mobility group box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005, 94:975-979.
67. Zeerleder S., Zwart B., Wuillemin W.A., Aarden L.A., Groeneveld A.B., Caliezi C., et al. Elevated nucleosome levels in systemic inflammation and sepsis. Crit Care Med 2003, 31:1947-1951.
68. Nakahara M., Ito T., Kawahara K.I., Yamamoto M., Nagasato T., Shrestha B., et al. Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism. PLoS One 2013, 8.
69. Abrams S.T., Zhang N., Manson J., Liu T., Dart C., Baluwa F., et al. Circulating histones are mediators of trauma-associated lung injury. Am J Respir Crit Care Med 2013, 187:160-169.
70. Dwivedi D.J., Toltl L.J., Swystun L.L., Pogue J., Liaw K.L., Weitz J.I., et al. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care 2012, 16:R151.
71. Savchenko A.S., Martinod K., Seidman M.A., Wong S.L., Borissoff J.I., Piazza G., et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J Thromb Haemost 2014, 12:860-870.
72. Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013, 13:34-45.
73. Fuchs T.A., Brill A., Duerschmied D., Schatzberg D., Monestier M., Myers D.D., et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010, 107:15880-15885.
74. Massberg S., Grahl L., von Bruehl M.L., Manukyan D., Pfeiler S., Goosmann C., et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010, 16:887-896.
75. Leung L.L., Myles T., Nishimura T., Song J.J., Robinson W.H. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI). Mol Immunol 2008, 45:4080-4083.
76. Zhao X., Chen Y.X., Li C.S. Predictive value of the complement system for sepsis-induced disseminated intravascular coagulation in septic patients in emergency department. J Crit Care 2015, 30:290-295.
77. Feng S., Liang X., Kroll M.H., Chung D.W., Afshar-Kharghan V. von Willebrand factor is a cofactor in complement regulation. Blood 2015, 125:1034-1037.
78. Behnes M., Bertsch T., Lepiorz D., Lang S., Trinkmann F., Brueckmann M., et al. Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment. Crit Care 2014, 18:507.
79. Ishikura H., Nishida T., Murai A., Nakamura Y., Irie Y., Tanaka J., et al. New diagnostic strategy for sepsis-induced disseminated intravascular coagulation: a prospective single-center observational study. Crit Care 2014, 18:R19.